Physician profile
Heath E Scott
NPI 1205881489
$1,130.05
in general payments reported to CMS, 2019-2025
25 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.01 · 2020: $26.98 · 2021: $202 · 2022: $211 · 2023: $46.80 · 2024: $218 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $209.73 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $105.98 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.41 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $84.75 | 2021-2022 | |
| Amgen INC. | $79.54 | 2025 | Otezla, Repatha, Evenity |
| Teva Pharmaceuticals USA, INC. | $72.93 | 2025 | Austedo Xr |
| Lilly USA, LLC | $61.27 | 2024-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $59.68 | 2019-2024 | |
| Lundbeck LLC | $52.25 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.47 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $31.40 | 2021 | |
| Novo Nordisk INC | $29.87 | 2022-2024 | Rybelsus, Tresiba, Ozempic |
| Glaxosmithkline, LLC. | $26.33 | 2022-2025 | Arexvy, Trelegy Ellipta |
| Mylan Specialty L.P. | $24.75 | 2024 | Yupelri |
| Phathom Pharmaceuticals, INC. | $23.10 | 2024 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.72 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.50 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $14.40 | 2024 | Nuedexta |
| Merck Sharp & Dohme LLC | $14.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.93 | 2021 | |
| Hikma Pharmaceuticals USA | $12.67 | 2022 | |
| Sanofi Pasteur INC. | $12.45 | 2019 | |
| Grt US Holding, INC. | $11.04 | 2022 | |
| Boston Scientific Corporation | $10.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heath Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.